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T he insertion of a self-expandable metal stent (SEMS) is the first-line option for an unresectable 
malignant distal biliary stricture.  Compared to tradi-
tional plastic stents,  SEMSs allow for good drainage 
and high patency rates [1-3].  A SEMS costs more than 
a plastic stent,  but its use results in fewer re-interven-
tions and hospital stays.  A SEMS is also a cost-effective 
palliative treatment for individuals with unresectable 
diseases [4 , 5].  However,  SEMSs are associated with 
some serious complications,  e.g.,  cholecystitis,  cholan-
gitis,  and pancreatitis.  Many mechanisms of post- 
endoscopic retrograde cholangiopancreatography pan-
creatitis (PEP) have been suggested; one is main pan-
creatic duct (MPD) obstruction due to papillary swell-
ing during the procedure [6-10].  In order to solve this 
problem and prevent PEP,  endoscopic pancreatic stent-
ing (EPS) for individuals at high risk of developing PEP 
is recommended by international guidelines [11-14].
We have performed SEMS insertions for malignant 
distal biliary strictures with biliary sphincterotomy,  and 
we sometimes observe PEP in patients without MPD 
obstruction.  Shimizu et al.  and Kawakubo et al.  revealed 
that nonpancreatic cancer is a risk factor predicting PEP 
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The insertion of a self-expandable metal stent (SEMS) for nonpancreatic cancer is a factor predicting the risk of 
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP).  We evaluated the efficacy of endo-
scopic pancreatic stenting (EPS) to prevent PEP after SEMS insertion in patients with malignant distal biliary 
stricture and without main pancreatic duct (MPD) obstruction.  We performed a single-center,  retrospective,  
historically controlled investigation to assess the outcomes of 33 consecutive patients who underwent SEMS 
insertion.  From March 2013 to June 2015,  13 patients did not undergo EPS (Non-EPS group).  The other 20 
patients underwent EPS (EPS group) between July 2015 and August 2018.  The background data demonstrated 
no significant differences.  Except for one patient in the Non-EPS group,  all patients underwent biliary sphinc-
terotomy.  The EPS group’s PEP incidence was significantly lower (n = 1,  5%) than that of the Non-EPS group 
(n = 4,  31%) (p= 0.04).  The median serum amylase and lipase levels after the procedure were significantly lower 
in the EPS group than in the Non-EPS group (amylase: 104 vs. 262 U/L; p< 0.01,  lipase: 102 vs. 666 U/L;  
p= 0.01).  The use of EPS decreased the incidence of PEP after SEMS insertion in individuals with malignant 
distal biliary stricture and without MPD obstruction.
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after SEMS placement in patients with a distal malig-
nant biliary stricture,  because MPD tumor involvement 
is low and exocrine function is usually preserved in 
patients with nonpancreatic cancer [15 , 16].  However,  
no study has evaluated the efficacy of EPS following 
SEMS insertion in patients with a distal malignant bili-
ary stricture with nonpancreatic cancer.  We have thus 
introduced the routine use of EPS following SEMS 
insertion in individuals with a distal biliary stricture 
without MPD obstruction,  with the goals of preventing 
the SEMS from compressing the MPD and of decreas-
ing PEP risk.  We performed the present investigation to 
determine the efficacy of EPS for the prevention of PEP 
after SEMS insertion in patients without MPD obstruc-
tion.
Patients and Methods
Patients. All of the patients in this study were 
identified from our endoscopic retrograde cholan-
giopancreatography (ERCP) database.  Between March 
2013 and August 2018,  83 patients underwent a SEMS 
insertion for a distal biliary stricture.  All of these 
patients underwent an examination including a com-
puted tomography (CT) scan and/or magnetic reso-
nance imaging before undergoing the ERCP.  By using 
the findings of those examinations,  we excluded 
patients with MPD obstruction and/or dilatation of the 
MPD > 4 mm (n = 38).  Patients with a history of SEMS 
insertion (n = 9) and patients with a benign biliary stric-
ture (n = 3) were excluded as well.  We thus retrospec-
tively investigated the cases of 33 patients.
Of the 33 patients,  13 underwent a SEMS insertion 
between March 2013 and June 2015 and did not 
undergo the insertion of a pancreatic stent (Non-EPS 
group).  The other 20 patients who underwent SEMS 
insertion between July 2015 and August 2018 under-
went a pancreatic stent insertion (EPS group) (Fig. 1).  
These two periods were mutually exclusive.  The Ethics 
Committee of our institute approved the study design 
(Japanese Red Cross Okayama Hospital,  2018-84),  and 
the study adhered to the Declaration of Helsinki.  
Before each ERCP,  the patient provided written 
informed consent to undergo the procedure and for the 
data to be used.
SEMS procedures. The deployed stent was a 
5-French straight pancreatic stent with various lengths 
(3-7 cm) (Geenen: Cook Endoscopy,  Winston-Salem,  
NC,  USA).  Four SEMS were used: WallFlex (Boston 
Scientific; Natick,  MA,  USA); X-Suit NIR (Olympus;  
Tokyo); BONA Stent (Medicos-Hirata; Osaka,  Japan);  
and Niti-S (Taewoong Medical; Seoul,  Korea).  Each 
ERCP was conducted with a JF-260V or TJF-260V 
video endoscope (Olympus Medical; Tokyo) with the 
patient under conscious sedation (midazolam,  pethi-
dine hydrochloride).  Selective MPD or common bile 
duct cannulation was first attempted using an ERCP 
Catheter (MTW Endoscopie; Wesel,  Germany) and a 
0.025-inch guidewire (VisiGlide or VisiGlide2: Olympus 
Medical Systems,  Tokyo).  A guidewire-assisted cannu-
lation technique was attempted as the first option; if 
this proved difficult,  a more conventional contrast- 
assisted cannulation method was used.  After biliary 
cannulation,  the guidewire was passed through the bil-
iary stricture and then placed in the intrahepatic bile 
duct.  A sphincterotomy with a moderate incision was 
achieved with a blended current.  A moderate incision 
was defined as one that exceeded the transverse fold and 
did not reach the superior margin of the papillary bulge,  
according to the Japan Gastroenterological Endoscopy 
Society guidelines for endoscopic sphincterotomy [17].  
The SEMS was then inserted over the guidewire by 
using a fluoroscopic control.
In the EPS group,  generally,  the patients were can-
nulated by the double-guidewire method in biliary can-
nulation.  If pancreatic cannulation proved difficult,  we 
cannulated to a pancreatic duct after a biliary sphincter-
otomy or a precut papillotomy.  The pancreatic stent was 
inserted (under fluoroscopic control) over the guide-
wire before the SEMS insertion (Fig. 2).  In the Non-EPS 
group,  we tried not to cannulate MPD and completed 
the procedure without EPS.  If the ERCP training fellow 
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Fig. 1　 Trial profile.
could not obtain an endoscopic retrograde pancreatog-
raphy (ERP) or endoscopic retrograde cholangiography 
(ERC) image within 10 min,  two senior endoscopists 
with a total career length of more than 10 years and 
experience with 2,000 ERCPs helped obtain the ERP or 
ERC image.  When it took longer than 10 min to achieve 
a successful selective cannulation,  the procedure was 
categorized as difficult.
The stent type was chosen by the operator to achieve 
the safest and most successful procedure.  The pancre-
atic stent was not removed unless and until it clogged 
and caused pancreatitis.  We infused 150,000 U of uli-
nastatin (Mochida Pharmaceutical,  Tokyo,  Japan) dis-
solved in 100 mL of 0.9% saline solution immediately 
after the ERCP throughout the study period.  In both 
patient groups,  diclofenac was administered at the dis-
cretion of each endoscopist.  We defined ʻadverse 
eventsʼ in accord with the lexicon of endoscopic adverse 
events issued by the American Society Gastrointestinal 
Endoscopy [18]; ERCP-related adverse events were 
defined in accord with the European Society of 
Gastrointestinal Endoscopy Guideline [11].
Definitions of post-ERCP pancreatitis. We 
defined ʻPEPʼ based on the standard criteria [11]: new 
abdominal pain or worsening abdominal pain persisting 
for ≥ 24 h after the ERCP,  in addition to a serum amy-
lase level or a serum lipase level > 3 times the upper 
limit of normal.  We also graded pancreatitis according 
to the standard criteria [11]: ʻmildʼ,  no organ failure 
and no local or systemic complications; ʻmoderateʼ,  
transient ( < 48 h) organ failure and/or local or systemic 
complications without persistent organ failure; and 
ʻsevereʼ,  persistent (48 h) organ failure.
Statistical analysis. The study’s primary end-
point was the development of PEP.  We compared cate-
gorical variables and continuous variables between the 
EPS and Non-EPS groups by using the χ2 test and the 
Mann-Whitney U-test.  P-values < 0.05 were accepted as 
significant.  All statistical analyses were conducted using 
the JMP ver. 12.2.0 statistical software package (SAS 
Institute,  Cary,  NC,  USA).
Results
Patient characteristics and procedures. The 
background data demonstrated no significant between-
group differences (Table 1).  In both groups,  the pri-
mary diseases included pancreatic cancer,  biliary can-
cer,  gastric cancer,  and colon cancer.  One ovarian 
cancer was included in the EPS group.  Four patients 
(20%) in the EPS group and 4 (31%) in the Non-EPS 
group were given analgesic drugs for abdominal pain 
before ERCP.  Fifteen patients (75%) had naïve papilla in 
the EPS group,  as did 6 (46%) in the Non-EPS group 
(p = 0.14).  In the EPS group,  pancreatography was per-
formed in all patients for the deployment of the pancre-
atic stents,  whereas only 6 (46%) patients in the Non-
EPS group underwent pancreatography (p < 0.01).  In the 
Non-EPS group,  only one patient did not undergo bili-
ary sphincterotomy and 2 patients underwent insertion 
of uncovered SEMS.  Regarding the marker for proce-
dure difficulty,  more than 10 min elapsed for successful 
selective cannulation in 4 patients (20%) in the EPS 
group and in 3 patients (23%) in the Non-EPS group 
(Table 2).  EPS was successful in all 20 patients in the 
EPS group.
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Fig. 2　 Placement of pancreatic stent and fully covered metal stent.  A,  Fluoroscopic imaging; B,  Endoscopic imaging.
Pancreatitis, hyperamylasemia, and serum levels of 
amylase and lipase. One of the 20 EPS patients (5%) 
and 4 of the 13 Non-EPS patients (31%) developed PEP 
(p = 0.04) (Table 3).  The one EPS group patient who 
developed moderate PEP.  However,  all cases of PEP 
resolved with conservative therapy without SEMS 
removal.  There was no significant between-group dif-
ference in the incidence of hyperamylasemia (p = 0.11).  
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Table 3　 Incidence of pancreatitis and hyperamylasemia and serum levels of amylase and lipase
EPS (n=20) Non-EPS (n=13) p-value




Hyperamylasemia 3 (15%) 7 (54%) 0.11
Serum amylase,  U/L; median (IQR)
　Before 72 (40-84) 65 (55-94) 0.52
　18 h after procedure 104 (54-169) 262 (147-1,392) <0.01
Serum lipase,  U/L; median (IQR)
　Before 42 (20-75) 62 (28-101) 0.63
　18 h after procedure 102 (33-216) 666 (134-1,850) 0.01
IQR,  interquartile range.
Table 1　 Baseline characteristics of the patients
EPS (n=20) Non-EPS (n=13) p-value
Mean age,  year (range) 80 (67-95) 74 (45-90) 0.37
Males/Females 13/7 9/4 0.99
Primary disease (Pancreatic cancer/Biliary cancer/
Gastric cancer/Colon cancer/Ovarian cancer) 4/10/1/4/1 3/6/3/1/0 0.46
Administration of analgesic drugs for abdominal pain 4 (20%) 4 (31%) 0.68
Previous post ERCP pancreatitis 0 1 0.39
Mean main pancreatic duct dia.,  mm (range) 2.4 (1-4) 2.0 (1-4) 0.23
Administered diclofenac 3 (15%) 2 (15%) 0.98
Observation period,  days; median (IQR) 159 (85-373) 231 (35-283) 0.47
ERCP,  endoscopic retrograde cholangiopancreatography; IQR,  interquartile range.
Table 2　 ERCP findings and endoscopic procedure
EPS (n=20) Non-EPS (n=13) p-value
Naïve papilla 15 (75%) 6 (46%) 0.14
Duodenal diverticulum 1 (5%) 1 (8%) 0.75
Previous biliary plastic stent 5 (25%) 7 (54%) 0.14
Pancreatography 20 (100%) 6 (46%) <0.01
Precut＊ 2 (10%) 1 (8%) 0.82
Biliary sphincterotomy 20 (100%) 12 (92%) 0.40
More than 10 minutes elapsed for the successful
selective cannulation 4 (20%) 3 (23%) 0.99
Mean procedure time,  min (range) 28 (15-36) 30 (16-73) 0.46
Trainee participation 8 (40%) 3 (23%) 0.31
Stent type (covered/uncovered) 20/0 11/2 0.15
＊Precut include precut papillotomy and transpancreatic sphincterotomy.
ERCP,  endoscopic retrograde cholangiopancreatography.
The median serum amylase level and the median serum 
lipase level at 18 h after the procedure were both signifi-
cantly lower in the EPS group than in the Non-EPS 
group (amylase: 104 vs. 262 U/L; p < 0.01,  lipase: 102 
vs. 666 U/L; p = 0.01) (Table 3,  Fig. 3).
Other complications. No other major early com-
plications were observed.  SEMS dislodgement was 
observed after approx.  18 months in one EPS group 
patient.  Mild pancreatitis was observed in one EPS 
group patient after 1 month,  but this resolved with con-
servative therapy and without the need for pancreatic 
stent extraction.
Discussion
A biliary SEMS is the first option for an unresectable 
malignant distal biliary stricture.  Previous studies 
showed a comparatively high frequency of acute adverse 
events caused by mechanical stent compression,  such as 
cholecystitis and pancreatitis [15 , 16 , 19].  Some cases of 
pancreatitis have required the immediate removal of a 
stent after its insertion.  Itoi et al.  reported the case of a 
patient with lethal PEP after SEMS insertion in a distal 
biliary stricture due to unresectable cholangiocarci-
noma [20]; the SEMS was removed just 2 days after the 
procedure.  However,  the PEP worsened and the patient 
died.  Itoi et al.  suggested 2 major mechanisms of PEP 
after SEMS insertion.  One is MPD opacification during 
the ERCP procedure: namely,  common PEP.  The other 
mechanism is impaired drainage from the MPD due to 
SEMS compression toward the papilla.  Based on their 
patient’s clinical course,  Itoi et al.  concluded that the 
expansive force of the SEMS caused the patient’s PEP.
The present report is the first to reveal that using EPS 
decreased the rate of PEP in individuals without MPD 
obstruction,  even though all 20 of the patients in the 
EPS group underwent pancreatography.  This may sup-
port the theory that MPD obstruction caused by the 
expansive force of the SEMS is the most important fac-
tor for PEP after the insertion of a SEMS in a distal bili-
ary stricture.
Shimizu et al.  and Kawakubo et al.  revealed that 
nonpancreatic cancer was one of the predictive risk fac-
tors for PEP after SEMS insertion in a distal biliary 
stricture [15 , 16].  Isayama et al.  and Nakai et al.  showed 
that the rate of PEP in individuals with MPD obstruc-
tion by their tumors was low [21 , 22].  Usually,  most 
patients with pancreatic head cancer also show MPD 
involvement by the tumor,  and the pancreatic paren-
chyma of the distal part is atrophic.  They thus have 
impaired exocrine function.  However,  in patients with 
nonpancreatic cancer,  the MPD is not completely 
obstructed and exocrine function of the pancreas is pre-
served.  In accord with this theory,  we conducted the 
present study with patients without MPD obstruction.
Insertion to a pancreatic duct is sometimes difficult,  
and a failure in pancreatic duct cannulation presents a 
risk of PEP.  In our patient series,  EPS was successfully 
inserted in all EPS group patients.  Fifteen patients were 
cannulated to the pancreatic duct first; one patient 
required a precut papillotomy and 4 required a biliary 
sphincterotomy for cannulation into the pancreatic 
duct.  It is widely known that cannulation after a biliary 
sphincterotomy is a comparatively easy way to cannu-
late a pancreatic duct.  After a biliary sphincterotomy,  it 
is easy to identify the pancreatic duct.













































Fig. 3　 Comparison of serum amylase and lipase levels between EPS and Non-EPS groups after endoscopic retrograde cholangiopan-
creatography.  Both serum amylase and lipase levels were significantly lower in the EPS group than in the Non-EPS group (p<0.01,  
p=0.01,  respectively).
Mild pancreatitis as a late complication was observed 
in only one of our EPS group patients (at ~ 1 month 
after the procedure),  and it resolved with conservative 
therapy and without the removal of the pancreatic stent.  
The reason why other patients did not have pancreatitis 
is unknown.  We speculate that because the 5-Fr pan-
creatic stent is thin,  pancreatic juice could leak out 
through the peripheral space around the pancreatic 
stent.  Late adverse events are an important concern 
with this method,  and careful observation of these 
patients is necessary.  However,  it may be easy to 
exchange a pancreatic stent because we can easily iden-
tify the pancreatic duct orifice after pancreatic stent 
extraction.  When there is no pancreatic stent,  it might 
be difficult to find the pancreatic duct orifice after SEMS 
placement.
Our study has some limitations.  The number of 
patients was relatively low,  and the study design was 
retrospective.  Due to the small number of patients,  it 
may not be possible to conclude whether EPS can 
prevent PEP in patients without MPD obstruction.  
Second,  the imaging confirmation of PEP was not done 
by CT scan due to our investigation’s retrospective 
design.  The abdominal pain associated with PEP can be 
difficult to distinguish from the abdominal pain related 
to SEMS expansion.  We used standard criteria:  
abdominal pain lasting ≥ 24 h and a high level of serum 
amylase or serum lipase.  Abdominal pain may include 
the pain associated with stent expansion.  We therefore 
also compared the serum amylase and lipase levels in 
both groups.  Third,  the PEP rate in the Non-EPS 
patients was high (31%),  but this value is similar to the 
28% in another study of nonpancreatic cancer patients 
[15].
In summary,  our analyses demonstrated that the 
PEP incidence was reduced and the serum amylase and 
serum lipase levels 18 h post-ERCP were lower in EPS 
patients than in non-EPS patients.  The use of EPS 
decreased the rate of PEP in patients without MPD 
obstruction after the insertion of a SEMS.  Although 
additional studies with larger numbers of patients and 
prospective randomized controlled studies are needed,  
we recommend the use of endoscopic pancreatic stent-
ing before SEMS insertion in patients without MPD 
obstruction for the prevention of PEP.
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